Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sumitomo Dainippon Pharma Co ( (JP:4506) ) has issued an update.
Sumitomo Pharma Co., Ltd. has completed a company split and share transfer of its Asian business to Marubeni Global Pharma Corporation, resulting in Sumitomo Pharma (China) and Sumitomo Pharma Asia Pacific no longer being its consolidated subsidiaries. This strategic move is expected to generate approximately 45 billion yen in gains, which will be utilized to strengthen the company’s financial foundation and focus on growth initiatives.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd., headquartered in Osaka, Japan, operates in the pharmaceutical industry. The company focuses on developing and providing pharmaceutical products and services, with a market presence in Asia through its subsidiaries.
Average Trading Volume: 12,362,924
Technical Sentiment Signal: Buy
Current Market Cap: Yen451.7B
For detailed information about 4506 stock, go to TipRanks’ Stock Analysis page.